Buy, hold, sell: Deep Yellow, PLS, Pro Medicus shares

Morgans has given its verdict on these shares. Here's how it rates them.

If you are in the market for some new portfolio additions, it could be worth seeing what the team at Morgans is saying about the three ASX shares in this article. 

Does the broker rate them as buys, holds, or sells? Let's find out:

Man with hand to his forehead looking at his laptop.

Image source: Getty Images

Deep Yellow Ltd (ASX: DYL)

Morgans highlights that this uranium developer's final investment decision (FID) for the Tumas project is behind schedule due to uncertain equity market and funding conditions.

Nevertheless, it remains positive and sees an opportunity for investors with a higher tolerance for risk to buy its shares. It has retained its speculative buy rating with a reduced price target of $1.50. Morgans said:

DYL has withdrawn its targeted 4Q26 Final Investment Decision (FID) for Tumas, citing weakness in equity market conditions and a constrained funding backdrop for uranium developers. The FID deferral is not entirely surprising given the weakness in DYL's share price over recent months. In our view, raising equity at current levels would have represented an unattractive funding outcome for existing shareholders. 

Importantly, we view this as a delay rather than a change in strategy, with DYL remaining focused on advancing Tumas and positioning the project for a future FID. We maintain our rating of SPECULATIVE BUY with a price target of A$1.50ps (previously A$1.95ps).

PLS Group Ltd (ASX: PLS)

One ASX share that has made an FID this month is lithium miner PLS. 

The decision was a touch mixed with higher capital expenditure but also higher steady-state production. As a result, the broker has retained its accumulate rating on PLS shares with a $3.70 price target. It said:

PLS has taken FID on the ~A$1.9bn P2000 expansion, lifting capacity to ~2Mtpa (from ~1.2Mtpa) with first production targeted in 1Q FY30. P2000 capex is ~20% above MorgansF, but steady-state production is higher (+16%) and sustaining + mine development spend lower (-14%). Maintain ACCUMULATE with A$3.70ps target price.

Pro Medicus Ltd (ASX: PME)

Now could be a good time to buy Pro Medicus shares according to Morgans.

In response to a new contract win, the broker has upgraded its shares to a buy rating with a $230.00 price target. It commented:

PME has announced a further seven-year, A$24m full stack cloud contract with Billings Clinic Logan Health, its third new community health system win in FY27 to date (A$72m TCV, A$10.3m new ARR). The FY27 wins are modest individually but consistent in size, term and scope, pointing to a repeatable mid-market playbook that broadens the pipeline beyond large Integrated Delivery Networks. 

Near-term focus shifts to RSNA in late November as the likely window for a larger deal, and to execution on a busy 1Q'CY27 go-live schedule underpinning FY28. We upgrade to a BUY (from Accumulate), with no change to our A$230 target price.

Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Two male ASX investors and executives wearing dark coloured suits sit at a table holding their mobile phones discussing the highest trading ASX 200 shares today
Broker Notes

Buy, hold, sell: Resmed, Goodman Group, CBA shares

We review three fresh buy, hold, and sell calls from John Athanasiou at Red Leaf Securities.

Read more »

colleagues on a lunch break looking at iPhone
Broker Notes

Top brokers name 3 ASX shares to buy now

Here's what brokers are recommending as buys this week.

Read more »

Woman with her fingers crossed and eyes shut.
Broker Notes

7 ASX 200 shares in the buy zone as optimism returns to the market: experts

Brokers reaffirmed their buy calls on Liontown, Rio Tinto, Xero, and others this week.

Read more »

ASX shares broker ratings represented by three different coloured buttons.
Broker Notes

6 ASX shares upgraded and downgraded by the experts this week

Brokers have changed their ratings and 12-month price targets on Qantas, Codan, and others. 

Read more »

A woman sits in a cafe wearing a polka dotted shirt and holding a latte in one hand while reading something on a laptop that is sitting on the table in front of her
Broker Notes

Buy, hold, sell: CSL, NextDC, PLS shares

Mark Elzayed from Vestra Capital explains his ratings on three ASX 200 shares.

Read more »

Buy, hold, and sell ratings written on signs on a wooden pole.
Broker Notes

Eagers Automotive, REA Group, National Australia Bank: Buy, sell, or hold?

The leader of this pack might surprise.

Read more »

Man sitting in a plane seat works on his laptop.
Broker Notes

Qantas shares were just downgraded but I still rate them as a buy

I think the downgrade was wrong and see value in the airline's shares.

Read more »